Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: A US perspective

Current Medical Research and Opinion

Volumn 25, Issue 5, 2009, Pages 1221-1234

  Nuijten, Mark ^a   Andress, Dennis L ^b   Marx, Steven E ^b   Sterz, Raimund ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CINACALCET; PARICALCITOL; VITAMIN D RECEPTOR;

ARTICLE; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; MORTALITY; PREVALENCE; PROBABILITY; PROCESS MODEL; PROTEINURIA; QUALITY ADJUSTED LIFE YEAR; SECONDARY HYPERPARATHYROIDISM; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

ALGORITHMS; CALCITRIOL; CASE-CONTROL STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ERGOCALCIFEROLS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MARKOV CHAINS; MODELS, BIOLOGICAL; RENAL INSUFFICIENCY, CHRONIC; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 67649406105     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902844097     Document Type: Article

References (60)

1. Alebiosu CO, Ayodele OE. The global burden of chronic kidney disease and the way forward. Ethn Dis 2005;15:418-423 (Pubitemid 41245551)
2. Obrador GT, Pereira BJ, Kausz AT. Chronic kidney disease in the United States: an underrecognized problem. Semin Nephrol 2002;22:441-448 (Pubitemid 35351257)
3. Nissenson AR, Pereira BJ, Collins AJ, et al. Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization. Am J Kidney Dis 2001;37:1177-1183 (Pubitemid 32525153)
4. White SL, Cass A, Atkins RC, et al. Chronic kidney disease in the general population. Adv Chronic Kidney Dis 2005;12:5-13 (Pubitemid 40255598)
5. McKenna K, Thompson C. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus. Scott Med J 1997;42:99-104 (Pubitemid 27390265)
6. Bakris GL. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens 1996;5:219-223 (Pubitemid 26194553)
7. Uhlig K, Levey AS, Sarnak MJ. Traditional cardiac risk factors in individuals with chronic kidney disease. Semin Dial 2003;16:118-127 (Pubitemid 37356824)
8. Lewis EJ, Lewis JB. Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clin Exp Nephrol 2003;7:1-8 (Pubitemid 36460535)
9. Weir MR. The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. Am J Hypertens 2005;18:100-5S (Pubitemid 40544826)
10. Bakris GL. Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens 2005;18:112-19S (Pubitemid 40544828)
11. USRDS. Patient Mortality and Survival. US Renal Data System, USRDS 1998, Annual Data Report. The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 1998: 63-78. Available from: www.usrds.org. Accessed May 13, 2004
12. Bloembergen WE. Cardiac disease in chronic uremia: epidemiology. Adv Ren Replace Ther 1997;4:185-193 (Pubitemid 27304994)
13. Barrett BJ. Applying multiple interventions in chronic kidney disease. Semin Dial 2003;16:157-164 (Pubitemid 37356828)
14. Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial 2004;17:209-216 (Pubitemid 38824502)
15. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006;69:33-43 (Pubitemid 43117736)
16. Saleh FN, Schirmer H, Sundsfjord J, et al. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003;24:2054-2060 (Pubitemid 37420453)
17. Daisley-Kydd RE, Mason NA. Calcitriol in the management of secondary hyperparathyroidism of renal failure. Pharmacotherapy 1996;16:619-630 (Pubitemid 26285914)
18. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115-1121
19. Yudd M, Llach F. Current medical management of secondary hyperparathyroidism. Am J Med Sci 2000;320:100-106 (Pubitemid 30664182)
20. Tuma SN, Martin RR, Mallette LE, et al. Augmented polymorphonuclear chemiluminescence in patients with secondary hyperparathyroidism. J Lab Clin Med 1981;97:291-298 (Pubitemid 11136132)
21. Chervu I, Kiersztein M, Alexiewicz JM, et al. Impaired phagocytosis in chronic renal failure is mediated by secondary hyperparathyroidism. Kidney Int 1992;41:1501-1505
22. Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 1997;30:606-620 (Pubitemid 27465354)
23. Huraib S, Tanimu D, Romeh SA, et al. Effects of intravenous alfacalcidol on lymphocyte phenotyping in hemodialysis patients. Am J Kidney Dis 1998;32:1036-1040 (Pubitemid 28551168)
24. Rubinger D, Friedlander MM, Silver J, et al. Progressive vascular calcification with necrosis of extremities in hemodialysis patients: a possible role of iron overload. Am J Kidney Dis 1986;VII:125-129 (Pubitemid 16141323)
25. Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004;19:V2-8 (Pubitemid 39214193)
26. Zandi-Nejad K, Brenner BM. Strategies to retard the progression of chronic kidney disease. Med Clin North Am. 2005;89:489-509 (Pubitemid 40332394)
27. Mix TC, St Peter WL, Ebben J, et al. Hospitalization during advancing chronic kidney disease. Am J Kidney Dis 2003;42:972-981 (Pubitemid 37322914)
28. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999;159:1873-8029 (Pubitemid 29424707)
29. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complicat 2004;18:18-26 (Pubitemid 38332946)
30. Warnock DG. Inclusion of albumin as a target in therapy guidelines: guidelines for chronic kidney disease. Kidney Int 2004;92:121-123 (Pubitemid 43361448)
31. Llach F, Velasquez-Forero F. Secondary hyperparathyroidism in chronic renal failure; pathogenic and clinical aspects. Am J Kidney Dis 2001;38:20-33 (Pubitemid 33026103)
32. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kid Dis 1995;26:852-860
33. 2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999;10:980-985
34. 3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 2002;40:1283-1288
35. Martin KJ, Gonzales EA, Gellens M, et al. 19-Nor-1-a-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998;9:1427-1432 (Pubitemid 28354552)
36. Lindberg J, Martin KJ, Gonzalez EA, et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001;56:315-323 (Pubitemid 32923166)
37. Sprague S, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-1490 (Pubitemid 36350014)
38. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001;38:S45-50 (Pubitemid 33022205)
39. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005;68:2823-2828 (Pubitemid 43251029)
40. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-456 (Pubitemid 36910023)
41. Dobrez D, Mathes A, Amdahl M, et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical setting. Nephrol Dial Transplant 2004;5:1174-1181 (Pubitemid 38628138)
42. Nuijten, MJC. Cost-effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics 1998;4:433-455
43. TreeAge Software, Inc. Decision Analysis by TreeAge (DATA) Software. Williamstown, MA, 1996
44. Sonnenberg, F, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Mak 1993;13:322-338 (Pubitemid 24013155)
45. http://www.westegg.com/inflation
46. Nuijten MJC. Data management in modelling studies: the selection of data sources. Pharmacoeconomics 1998;3:305-316 (Pubitemid 28123370)
47. Keith D, Nicholas G, Gullion C, et al. Mortality of chronic kidney disease in a large HMO population. J Am Soc Nephrol 2002;13:620A
48. Bakris GL, Levin A, Molitch M, et al. Disturbances of serum 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] in patients with chronic kidney disease. J Am Soc Nephi 2005;16:495A
49. Smith D, Gullion C, Nichols G, et al. Cost of medical care for CKD and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004;15:1300-1306 (Pubitemid 38526011)
50. Kalantar-Zadeh K, Marx SE, Schumock G, et al. Examination of outcomes and costs of care among patient with chronic kidney disease and secondary hyperparathyroidism. J Am Soc Nephrol 2006;17:647A
51. Jones C, Roderick P, Harris S, et al. An evaluation of a shared primary and secondary care nephrology service for managing patients with moderate to advanced CKD. Am J Kidney Dis 2006;47:103-114 (Pubitemid 41828272)
52. Boulware LE, Jaar BG, Tarver-Carr ME, et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. J Am Med Assoc 2003;290:3101-3114 (Pubitemid 37548116)
53. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660-667 (Pubitemid 29517951)
54. Kiberd BA, Jindal KK. Routine treatment of insulindependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation. Am J Kidney Dis 1998;31:49-54 (Pubitemid 28116682)
55. Hogan TJ, Elliott WJ, Seto AH, et al. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics 2002;20:37-47 (Pubitemid 34155214)
56. Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005;68:2801-2808 (Pubitemid 43251026)
57. USRDS. Costs of CKD and ESRD 2005. USRDS Annual Data Report. Minneapolis, MN: USRDS
58. Dinneen S, Gerstein H. The association of microalbuminuria and mortality in non-insulin dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413-1418
59. Buxton MJ, Drummond MF, van Hout B. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-228 (Pubitemid 27296586)
60. Nuijten MJ, Rutten F. The incorporation of potential confounding variables in Markov models. Pharmacoeconomics 2003;21:941-950 (Pubitemid 37222568)